Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126355211 | 12635521 | 1 | I | 20160726 | 20160809 | 20160809 | EXP | E2B_00512546 | CA-HQ SPECIALTY-CA-2016INT000725 | INTERCHEM | 0.00 | A | F | Y | 0.00000 | 20160809 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126355211 | 12635521 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK | 201749 | |||||||||||
| 126355211 | 12635521 | 2 | SS | ENBREL | ETANERCEPT | 1 | (50 MG, 1 W) | 0 | 50 | MG | |||||||||
| 126355211 | 12635521 | 3 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | UNK | 0 | |||||||||||
| 126355211 | 12635521 | 4 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | 7.1429 MG, (300 MG,1 IN 6 W) | U | 0 | 300 | MG | |||||||
| 126355211 | 12635521 | 5 | SS | ARAVA | LEFLUNOMIDE | 1 | UNK | U | 0 | ||||||||||
| 126355211 | 12635521 | 6 | SS | PLAQUENIL /00072602/ | HYDROXYCHLOROQUINE DIPHOSPHATE | 1 | UNK | U | 0 | ||||||||||
| 126355211 | 12635521 | 7 | SS | IMURAN | AZATHIOPRINE | 1 | UNK | U | 0 | ||||||||||
| 126355211 | 12635521 | 8 | SS | GOLD | GOLD | 1 | UNK | U | 0 | ||||||||||
| 126355211 | 12635521 | 9 | SS | CYCLOSPORINE. | CYCLOSPORINE | 1 | UNK | U | 0 | ||||||||||
| 126355211 | 12635521 | 10 | SS | CIMZIA | CERTOLIZUMAB PEGOL | 1 | 14.2857 MG, (200 MG,1 IN 2 W) | U | 0 | 200 | MG | ||||||||
| 126355211 | 12635521 | 11 | SS | HUMIRA | ADALIMUMAB | 1 | 2.8571 MG, (40 MG,1 IN 2 W) | U | 0 | 40 | MG | ||||||||
| 126355211 | 12635521 | 12 | SS | ACTEMRA | TOCILIZUMAB | 1 | 22.8571 MG, (640 MG,1 IN 4 W) | U | 0 | 640 | MG | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126355211 | 12635521 | 1 | Rheumatoid arthritis |
| 126355211 | 12635521 | 2 | Rheumatoid arthritis |
| 126355211 | 12635521 | 3 | Rheumatoid arthritis |
| 126355211 | 12635521 | 4 | Rheumatoid arthritis |
| 126355211 | 12635521 | 5 | Rheumatoid arthritis |
| 126355211 | 12635521 | 6 | Rheumatoid arthritis |
| 126355211 | 12635521 | 7 | Rheumatoid arthritis |
| 126355211 | 12635521 | 8 | Rheumatoid arthritis |
| 126355211 | 12635521 | 9 | Rheumatoid arthritis |
| 126355211 | 12635521 | 10 | Rheumatoid arthritis |
| 126355211 | 12635521 | 11 | Rheumatoid arthritis |
| 126355211 | 12635521 | 12 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126355211 | 12635521 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126355211 | 12635521 | Blood iron abnormal | |
| 126355211 | 12635521 | Disease progression | |
| 126355211 | 12635521 | Drug intolerance | |
| 126355211 | 12635521 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126355211 | 12635521 | 2 | 200208 | 200505 | 0 | |
| 126355211 | 12635521 | 4 | 200509 | 200701 | 0 | |
| 126355211 | 12635521 | 10 | 201007 | 201103 | 0 | |
| 126355211 | 12635521 | 11 | 200701 | 201006 | 0 | |
| 126355211 | 12635521 | 12 | 201103 | 0 |